The drug regulator will consider emergency use approval for Covid vaccines developed by Zydus Cadila for children above 12 this week. The regulator's subject expert committee (SEC) will examine data submitted by Cadila, reports Sushmi Dey.
The Zydus Cadila vaccine has been tested on adults as well as on children above 12 and if the regulatory panel is satisfied with the data and records submitted by the firm, the vaccine will be approved for emergency use soon, officials said. An approval can hasten the opening of schools although vaccine supply will remain a concern.
“The preliminary assessment of the application submitted by the company is going on and we have sent it to the SEC for further consideration. The SEC will be meeting in the coming week, representatives of the company will be also asked to make presentations,” an official said.